wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
   Journals
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Archive
     Editorial staff
     Editorial board
     For authors
     Subscription
Otorhinolaryngology
Allergology Review



 Search in articles:
  Authority of Polish Society of Allergology




vol 5. no 2. June 2000  
 TABLE OF CONTENT

 Original articles
Effect of inhalation of low molecular weight heparin on some blood clotting parameters in patients with bronchial asthma
Artur Kwaśniewski, Maryla Krasnowska, Beata Korbuszewska-Gontarz

Low molecular weight heparin (nadroparin) in nebulization as an additional treatment was applied in 11 patients with bronchial asthma and chronic obstructive pulmonary disease as well as in 10 healthy controls. Heparin was nebulized twice a day, 15 kU per dose. At the beginning of the study and after 3 and 6 days of heparin treatment several parameters of the blood clotting were estimated both in treated and non-treated groups (e.g., APTT, fibrinogen, platelets, anti-Xa activity). Similar parameters were measured after 7, 8 and 9 days, although heparin was no longer administered at that time. Nadroparin increased serum anti-Xa activity in all subjects. This change was less pronounced in asthmatics, but tended to last longer than in controls (p<0.05). No changes in other estimated parameters were observed.
Alergia Astma Immunol 2000; 5(2): 123-127


keywords: heparyna drobnocząsteczkowa w inhalacji, układ krzepnięcia, astma oskrzelowa, LMWHeparin inhalation, blood clotting, bronchial asthma

pages: from 123 to 127



estimated time of download (75 kB)
broadband speed:561282565121024[kbps]
time:166322[sec]


You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.


Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.